gavreto.com
Home | GAVRETO® (pralsetinib)
Learn about GAVRETO for RET+ metastatic non–small cell lung cancer (mNSCLC) or advanced thyroid cancer. See Important Safety Information.
gavreto价格
Searching…
Web results
gavreto.com
GAVRETO Full Prescribing Information
GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
gavreto.com
GAVRETO Patient Information
Tell your healthcare provider if you plan to have any surgery before or during treatment with GAVRETO. ° You should not take GAVRETO for at least 5 days before surgery.
gavreto.com
Get to know - GAVRETO
Before taking GAVRETO, tell your healthcare provider about all of your medical conditions and all of the medicines you take. Take your prescribed dose of GAVRETO exactly as advised by your healthcare provider.
gavreto.com
GAVRETO Side Effects for mNSCLC | GAVRETO® (pralsetinib)
Learn more about the side effects of GAVRETO for metastatic non–small cell lung cancer. See Important Safety Information.
gavreto.com
What Is GAVRETO for mNSCLC? | GAVRETO® (pralsetinib)
Learn more about GAVRETO, what GAVRETO is, and how GAVRETO may help your metastatic non–small cell lung cancer. See Important Safety Information.
gavreto.com
Tips to Manage Side Effects for mNSCLC | GAVRETO® (pralsetinib)
Learn about tips to help mange side effects of GAVRETO for metastatic non–small cell lung cancer. See Important Safety Information.
gavreto.com
How Do I Take GAVRETO for Advanced Thyroid Cancer? | GAVRETO®...
Learn more about how to take GAVRETO, including dosing schedule, and tips for taking GAVRETO. See Important Safety Information.
gavreto.com
How GAVRETO May Help for mNSCLC | GAVRETO® (pralsetinib)
Learn about how GAVRETO may help people with RET+ NSCLC, based on results from a clinical study. See Important Safety Information.
gavreto.com
YOUR GUIDE TO - gavreto.com
It is not known if GAVRETO is safe and effective when used to treat cancers caused by abnormal RET genes in children for the treatment of NSCLC or in children younger than 12 years of age for the treatment of thyroid cancer.